O
Ocular Therapeutix is a clinical-stage biopharmaceutical company developing AXPAXLI, an investigational intravitreal hydrogel formulation of axitinib for retinal disease, currently in Phase 3 trials for wet AMD. The hiring mix—skewed heavily toward healthcare, operations, and manufacturing roles, with director and senior-level focus—and active projects around cGMP compliance, ERP implementation, and QC system qualification indicate a company transitioning from research into manufacturing scale-up and regulatory submission readiness.
Tech Stack 20 technologies
Core StackLinux Active Directory FMEA Windows macOS Azure Portal Microsoft 365 Endpoint Manager Eclipse Word Google Docs Adobe Acrobat HPLC UPLC GCP LIMS Veeva Vault Excel PowerPoint ADP Workforce Now
What Ocular Therapeutix, Inc. Is Building
◆Challenges
- Reducing complexity and burden of current standard of care
- Ensuring cgmp compliance
- Clinical trial enrollment challenges
- Access barriers
- Vendor management for data quality
- Reducing risk to the business
- Streamlining security processes
- Improving efficiency across security resources
- Cost savings and supply chain resilience
- Procurement process simplification
▲Active Projects
- Stability program
- Clinical trials leading to nda
- Payer/coverage pull-through initiatives
- Erp software implementation
- Procurement analytics monitoring
- Equipment implementation for qc systems
- Maintenance and qualification of qc systems
- Risk-based quality strategy implementation
- Audit scheduling and reporting
- Post-approval clinical research activities
Hiring Activity
25 roles · 15 in 30d
Department
Seniority
Notable leadership hires: Procurement Director, Market Access Advocacy Director, Medical Director
Company intelligence
